Seminair 28-04-2015 Dr. O.J. de Vries

25
Dr. O.J. de Vries

Transcript of Seminair 28-04-2015 Dr. O.J. de Vries

Page 1: Seminair 28-04-2015 Dr. O.J. de Vries

Dr. O.J.

de V

ries

Page 2: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Introduction

§  30 % of all people 65 and older fall ≥ once/year §  15 % falls ≥ twice/year. §  10% leads to injuries §  5 % leads to fractures: 1-2% hip fracture §  Big impact on quality of life. §  24% of 55 yr and over dies within a year following a hip fracture

Dr. O.J.

de V

ries

Page 3: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Dr. O.J.

de V

ries

Page 4: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Increased fall risk

§  Risk factors: §  Age §  Dementia §  Diminished visual acuity §  Low body weight §  Gait disorder §  Prior fall §  ≥ 4 generic drugs §  Psychofarmacologicaly active drugs §  Orthostatic hypotension

§  Interaction intrinsic/extrinsic factors

Dr. O.J.

de V

ries

Page 5: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Increased fall risk

§  Risk factors: §  Age §  Dementia §  Diminished visual acuity §  Low body weight §  Gait disorder §  Prior fall §  ≥ 4 generic drugs §  Psychofarmacologicaly active drugs §  Orthostatic hypotension

§  Interaction intrinsic/extrinsic factors

Dr. O.J.

de V

ries

Page 6: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Longitudinal Aging Study Amsterdam

§  1992: inclusion of 3107 participants 65 yr and older in and around Zwolle, Oss and Amsterdam

§  1995/1996: medical interview of 1509 participants

§  Fall registration during 3 years

Dr. O.J.

de V

ries

Page 7: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Benzodiazepines

§  Screening-instrument (STOPP): §  Especially avoid long-acting

benzodiazepines (half-life ≥ 24h) because of increased fall risk.

Dr. O.J.

de V

ries

Page 8: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

STOPP criteria

Gallagher et al, Age and Ageing 2008; 37: 673-9

Dr. O.J.

de V

ries

Page 9: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

STOPP criteria

Gallagher et al, Age and Ageing 2008; 37: 673-9

Dr. O.J.

de V

ries

Page 10: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Benzodiazepines

§  Screening-instrument (STOPP): §  Especially avoid long-acting

benzodiazepines (half-life ≥ 24h) because of increased fall risk.

§  Hypothese: §  Short-acting benzodiazepines (T1/2 ≤ 10h)

are also associated with an increased fall risk.

Dr. O.J.

de V

ries

Page 11: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Benzodiazepines

§  Screening-instrument (STOPP): §  Especially avoid long-acting

benzodiazepines (half-life ≥ 24h) because of increased fall risk.

§  Hypothese: §  Short-acting benzodiazepines (T1/2 ≤ 10h)

are also associated with an increased fall risk.

§  Result: §  Short-acting benzodiazepines are

associated with an increased fall risk.

De Vries, O.J. et al. Age and Ageing 2013;0:1-7

Dr. O.J.

de V

ries

Page 12: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Antacids

§  Literature: §  Protonpump inhibitor use is associated with increased fracture

incidence.

§  Hypothesis: §  PPI use is associated with more falls and fractures than other

antacids

§  Results: §  PPI use is not associated with increased fall incidence §  H2-blocker is associated with increased fall incidence.

Dr. O.J.

de V

ries

Page 13: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Frailty

§  Literature: §  Physical frailty is associated with increased fall risk

§  Hypothesis: §  Frailty according to LASA is also associated with increased fall

risk.

§  Result: §  Frailty according to LASA is associated with increased fall risk. §  Prior falls are at least as predictive.

De Vries O.J. et al. Osteoporosis International 2013; 24:2397-403

Dr. O.J.

de V

ries

Page 14: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Robinovitch S.N. et al. Lancet 2013;381:47-54

Dr. O.J.

de V

ries

Page 15: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Video capture of the circumstances of falls in elderly people residing in long-term care: an observational study.

§  227 falls of 130 persons (mean age 78 yr, SD 10)

§  Activities during fall: §  Walking forward 24% §  Standing 13% §  Sitting down 12% §  Start walking 9% §  Rising from a chair 9%

§  Cause of fall: §  Weight shifting 41% §  Trip or stumble 21% §  Hit or bump 11% §  Loss of support 11% §  Collapse 11% §  Slipping 3%

Robinovitch et al. Lancet 2013;381:47-54.

Dr. O.J.

de V

ries

Page 16: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

http://www.thelancet/cms/attachment/2024445407/2044188965/mmc1.mp4

Dr. O.J.

de V

ries

Page 17: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

CBO guideline (2004) “Prevention of falls in older persons”

Dr. O.J.

de V

ries

Page 18: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

The CBO fall guideline recommends:

§  Medication evaluation §  Balance and strength training §  Restore visual acuity §  Safety in and around home §  Estimate fracture risk §  Consider evaluation of heart rhythm disorders

§  Possibly the highest risk reduction can be achieved in high risk older persons.

Dr. O.J.

de V

ries

Page 19: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Multifactorial fall prevention study

§  Hypothesis: §  Multifactorial analysis and intervention in older

persons with increased fall risk leads to prevention of new falls.

§  Method: §  217 older persons in and around Amsterdam §  Recent fall (ED or general practitioner) §  Intervention and control group(106 vs 111) §  1 year fall follow-up (calendar) §  After 1 year measurement of QoL, mobility and

mood.

Dr. O.J.

de V

ries

Page 20: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Multifactorial fall prevention study

§  Results: §  No difference between intervention and control group in time to

first fall. §  In both groups decrease of the number of falls. §  No differences in secondary outcomes apart from mortality.

§  Discussion: §  A lot of interventions in the control group. §  Most potential participants refused: selection of the most

motivated. §  The type of physical therapy possibly led to increased fall risk.

Dr. O.J.

de V

ries

Page 21: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Medication reduction fall prevention

§  Hypothesis: §  Stopping or reducing fall-risk-increasing drugs in high

risk older persons leads to prevention of new falls.

§  Method: §  612 older persons in and around Rotterdam and

Amsterdam §  Recent fall (ED) §  Intervention and control group (319 vs 293) §  1 year registration of falls, GP and ED visits. §  After 1 year measurement of QoL.

Dr. O.J.

de V

ries

Page 22: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Medication reduction fall prevention

§  Results: §  No difference in time to 1st or 2nd fall nor in number of falls. §  40% of the FRIDs were necessary. §  36% of the medication reduction interventions failed.

§  Discussion: §  ≥50% of the FRIDs were not discontinued; compliance,

dependence, necessity? §  Possibly better effect with long-term physician-patient relation. Dr. O

.J. de

Vrie

s

Page 23: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Meta-analysis

§  Gillespie LD, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012

§  159 trials with 79,193 community dwelling participants

§  Results: §  Physical therapy or tai-chi: reduces both fall risk

and fall rate. §  Multifactorial fall prevention: reduces only fall rate. Dr. O

.J. de

Vrie

s

Page 24: Seminair 28-04-2015 Dr. O.J. de Vries

Valpreventie

Future

§  Studies of the relation between risk factors and effectivity of different interventions.

§  Studies of more effective fall prevention: medication, physical therapy, reduction of fear of falls, etc.

§  Clinically relevant and irrespective of dogmas

Dr. O.J.

de V

ries

Page 25: Seminair 28-04-2015 Dr. O.J. de Vries

Dr. O.J.

de V

ries